We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$240M
Cap. Flow %
-32.47%
Top 10 Hldgs %
67%
Holding
218
New
54
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Miscellaneous 77.12%
2 Healthcare 8.81%
3 Financials 5.55%
4 Technology 3.48%
5 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMCB icon
151
PUT
PharmaCyte Biotech
PMCB
$4.1M
$140K 0.02%
+441
New +$1.55K
PALI icon
152
Palisade Bio
PALI
$352M
$139K 0.02%
70
– –
FCEL icon
153
CALL
FuelCell Energy
FCEL
$1.22B
$134K 0.02%
+7
New +$1.39K
LFWD icon
154
PUT
ReWalk Robotics
LFWD
$20M
$127K 0.02%
10
-38
-79% -$4.72K
EQOS
155
PUT
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
$119K 0.02%
367
-121
-25% -$614
CRDF icon
156
PUT
Cardiff Oncology
CRDF
$104M
$113K 0.02%
170
+3
+2% +$19
EVOK
157
DELISTED
Evoke Pharma
EVOK
$107K 0.01%
569
+240
+73% +$40.5K
CTXR icon
158
PUT
Citius Pharmaceuticals
CTXR
$15.4M
$100K 0.01%
+20
New +$1K
NBRV
159
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$94K 0.01%
32
-17
-35% -$480
IO
160
CALL
DELISTED
ION Geophysical Corporation
IO
$92K 0.01%
692
+192
+38% +$271
PHIO icon
161
Phio Pharmaceuticals
PHIO
$11.8M
$83K 0.01%
377
-102
-21% -$21.3K
HCDIW
162
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIW
$83K 0.01%
148,975
-123,128
-45% -$87.7K
ROI
163
DELISTED
RiskOn International, Inc. Common Stock
ROI
$77K 0.01%
+487
New +$68.3K
BKYI
164
BIO-key International
BKYI
$3.84M
$70K 0.01%
111
+17
+18% +$10K
TCDA
165
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$68K 0.01%
146
– –
VTGN icon
166
PUT
VistaGen Therapeutics
VTGN
$10.5M
$67K 0.01%
+8
New +$695
PPBT
167
PUT
Purple Biotech
PPBT
$2.8M
$57K 0.01%
1
-9
-90% -$8.72K
ASLN
168
PUT
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$54K 0.01%
+8
New +$910
EVFM
169
PUT
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$54K 0.01%
48
-15
-24% -$188
NBRV
170
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$44K 0.01%
1,469
-842
-36% -$23.8K
CBAT icon
171
CBAK Energy Technology Ltd
CBAT
$88.6M
$41K 0.01%
17,548
-157,549
-90% -$524K
NTBL
172
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$41K 0.01%
6
– –
ATHX
173
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$41K 0.01%
12
+4
+50% +$152
SRGA
174
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$35K ﹤0.01%
+1,064
New +$39K
TTNP
175
PUT
DELISTED
Titan Pharmaceuticals
TTNP
$34K ﹤0.01%
9
-55
-86% -$2.41K
5 6
7
8 9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $240M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 77% of assets, down from 81% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 54 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.